27th August 2026

In the context of the global pharma ecosystem, the Asia-Pacific region has undergone an especially fundamental transformation. In previous years, innovation was concentrated in North America and Europe, with APAC primarily serving as a cost-effective manufacturing base. Today, this dynamic has shifted dramatically to make the Asia-Pacific a major centre for manufacturing, research & development and boundary-pushing drug delivery and packaging expertise.

This evolution reflects more than geographical redistribution of production capacity. The APAC region now hosts 111 active CDMOs, helping to create an ecosystem where packaging demand increasingly follows investment in biologics and outsourcing. These developments are a clear signal of APAC's evolution from a production centre to a strategic hub for innovation.

The four forces driving the region’s pharma growth

Four interconnected factors are driving the transformation of the pharma landscape in the Asia-Pacific: firstly, the rising demand for advanced therapies like biologics are  increasing demand for sterile primary packaging, cold-chain solutions and specialised materials. As biologics manufacturing expands across Singapore, South Korea, China and Japan, it creates an increased need for packaging requirements to scale up accordingly.

The second key consideration is continuing innovation in drug delivery. The rise of patient-administered therapies is driving growth in auto-injectors, smart inhalers and wearable delivery systems. Having ushered in a shift toward self-administration, the pharma industry now face new packaging challenges around usability, safety and patient compliance.

Digital transformation forms the third pillar thanks to the supply chain’s increasing reliance on smart packaging, AI-enabled inspection and digital manufacturing technologies to enhance traceability, quality assurance and visibility.

The final, but by no means least significant, factor driving pharmaceutical growth in APAC is a newfound spirit of regional collaboration. As packaging demand is becoming more frequently shaped by a network of global manufacturing hubs, rather than a single dominant market, adopting a distributed approach creates opportunities for specialisation and cross-border partnerships.

Developing a network of specialised manufacturing hubs

APAC's pharmaceutical packaging ecosystem operates across different regions through interconnected hubs, each contributing its own distinct capabilities. India leverages its established manufacturing infrastructure and cost advantages to lead in generics and active pharmaceutical ingredients (APIs). Furthermore, thanks to its expertise in high-volume production, its impressive CDMO scale capacity offers a foundation for packaging suppliers serving global markets.

Firstly, running across all of this activity, is a push to improve the packaging and logistics capabilities of the region to support the region's expanding pharmaceutical supply chains. China offers a combination of manufacturing scale with expanding biologics capacity, positioning itself as a major force in the production of both traditional and advanced pharmaceuticals. The country's investment in biologics manufacturing has led to the substantial need for more sophisticated packaging solutions.

South Korea’s established leadership in biologics and significant investments in advanced therapy manufacturing has led to a corresponding increase in demand for high-value packaging formats including prefilled syringes, cartridges and advanced glass solutions. Japan contributes advanced pharmaceutical expertise, particularly in precision manufacturing and quality systems.

Singapore's strategic position in APAC’s innovation network

Singapore operates as a regional coordination hub which combines strategic location with regulatory credibility and innovation ecosystem development. The country's pharmaceutical packaging market has shown remarkable growth, with a projected value of US$3.30 billion by 2032.

The country exemplifies APAC's evolution toward high-value pharmaceutical activities, receiving major investments from AstraZeneca (US$1.5 billion), AbbVie (US$223 million), Novartis (US$226 million), and BioNTech (US$200 million) in recent years. These focus on biologics production, fill-finish operations and clinical trial supply rather than more traditional volume-driven activities which usually attract this level of financial support.

Singapore's competitive advantage stems from its ability to combine advanced production capabilities with innovation, connectivity and regulatory confidence. The country's strategic location is supported by more than 25 free trade agreements, positioning it as a gateway into wider APAC markets. This connectivity, combined with the Biopolis research hub and national focus on Smart Industry adoption, has helped foster an environment conducive to packaging innovation.

How biologics manufacturing has created a packaging evolution

The expansion of biologics manufacturing across APAC is also having a fundamental impact on packaging requirements. Advanced therapies need sterile primary packaging formats including vials, prefilled syringes and cartridges, along with specialised materials like elastomers and high-barrier polymers.

Maintaining product stability throughout the supply chain requires cryogenic labelling, temperature monitoring technologies, specialised insulation systems and validated transportation networks, creating opportunities for packaging suppliers to integrate cold-chain solutions into their logistics. The complexity extends beyond primary packaging to encompass more sophisticated drug delivery systems like auto-injectors, wearable injectors and connected delivery devices.

One way pharma packaging is being reshaped across APAC is through digital transformation, particularly in the face of increasing product complexity and supply chain digitalisation. For example, as biologics require more advanced materials, and there is higher demand for flexible and modular packaging lines, supply chains need to be adapted to enable unit-level customisation.

Supply chain digitalisation involves the introduction of smart and tamper-evident labelling, automation and AI-driven quality control and sustainability initiatives. These provide enhanced traceability, reduced risk of contamination and improvements to wider operational efficiency. The integration of digital technologies supports APAC's position as an innovation hub by enabling more sophisticated solutions and supply chain management capabilities to be put into place.

How collaboration is defining the growth of APAC’s pharma sector

The increasing interconnectedness of the APAC pharmaceutical ecosystem offers a wealth of new opportunities for collaboration across the value chain. No single organisation delivers modern pharmaceutical packaging alone, making partnerships essential for success. Future growth depends on strengthening the ties between pharmaceutical companies, CDMOs, packaging suppliers, device manufacturers, technology providers and regulatory authorities.

By taking a more collaborative approach, the region’s pharma sector will be better able to leverage its distributed expertise and capabilities. Meanwhile the scale of APAC's outsourcing ecosystem shows the maturity of its manufacturing base; India and China may account for the majority of facilities, but biologics revenues are increasingly concentrated among highly specialised organisations.

APAC's transformation extends beyond manufacturing to encompass the entire pharmaceutical packaging value chain. The region's influence now spans from raw material sourcing and component manufacturing through to final packaging, distribution and patient delivery systems. This comprehensive capability development positions APAC as more than a regional market, establishing it as a global centre for pharmaceutical packaging innovation.